CVN424 not checked

Cerevance Beta, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
4 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Parkinson Disease
Main trialPhase 3
“This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.”In the company’s words, NCT06553027 on ClinicalTrials.gov

Other drugs for Parkinson Disease

All 87 drugs for Parkinson Disease

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Aug 2026 To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Phase 2Completed 6 Nov 2021 Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Phase 2Completed 30 Jan 2025 Early Parkinson's Disease Monotherapy With CVN424
Phase 1Completed 11 Nov 2022 Relative Bioavailability and Food Effect Study of CVN424
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CVN424

Following is part of Solo: you see every change to CVN424 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in